Pain News and Research

Latest Pain News and Research

Early rehabilitation improves neurofunctional outcome after surgery in children with spinal tumors

In children, primary spinal tumors comprise 4% of all tumors from the central nervous system. Spinal tumors can present with a variety of clinical signs and symptoms in children such as pain followed by motor regression, gait disturbance, sphincter dysfunction, sensory symptoms, torticollis, and kyphoscoliosis.

1 Apr 2014

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Patients with severe ischemic heart disease and heart failure can benefit from a new treatment in which stem cells found in bone marrow are injected directly into the heart muscle, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Veterans struggle with mental health problems

More than half of the 2.6 million Iraq and Afghanistan veterans say they struggle with physical or mental health problems as a result of their service and feel detached from civilian life, according to a poll conducted by The Washington Post and the Kaiser Family Foundation.

1 Apr 2014

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.

31 Mar 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Pacira Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL (bupivacaine liposome injectable suspension). The suite is housed at the company's Science Center Campus in San Diego, where EXPAREL is currently manufactured.

31 Mar 2014

Venaxis files 510(k) premarket submission with FDA for APPY1 Test

Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration.

31 Mar 2014

First Edition: March 31, 2014

Today's early morning highlights from the major news organizations offer assessments of the administration's campaign to get people signed up for health care and a look at the issues going forward after today's deadline for most enrollments.

31 Mar 2014

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to placebo in patients with high cholesterol.

31 Mar 2014

Dongkook Pharmaceutical to launch Probi Mage dietary supplement in South Korea

Probi has signed a distribution agreement with Dongkook Pharmaceutical Co., Ltd., based in Seoul, South Korea for the distribution of Probi´s gut health product, Probi Mage®. The Product will be launched under Probi's brand in South Korea in the second quarter of 2014.

31 Mar 2014

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

EKOS Corporation, a BTG International group company, notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States.

31 Mar 2014

Spouses who express emotions have better sexual, psychological and relational well-being

Spouses who regulate their emotions together in a satisfactory manner are more fulfilled sexually, psychologically, and relationally, among couples in which the woman has provoked vestibulodynia (PVD), also known as "vulvar vestibulitis".

31 Mar 2014

$Choosing better treatment for ankle fractures$

Choosing better treatment for ankle fractures

Many people associate ankle fractures with sports, but you don't have to be an athlete to develop a serious ankle injury. Ankle fractures, in which there is a partial or complete break in a bone, can happen to anyone. People can break an ankle after a fall, car accident or twisting injury.

29 Mar 2014

FG Xpress launches new revolutionary natural pain relief solution for muscle pains

FG Xpress launches a new revolutionary natural pain relief solution in the market. The PowerStrips from FG Xpress is a pain relief product designed to take away all kinds of muscle pains naturally and safely. The product is formulated with key ingredients that do not just target to lessen users' pain issues but also help rejuvenate their body.

29 Mar 2014

Integral Molecular announces new patent protecting use of lipoparticles for eliciting antibodies against protein targets

Integral Molecular, a leader in membrane protein antibody discovery, announces the issuance of a new patent protecting the use of Lipoparticles for eliciting antibodies against membrane protein targets.

29 Mar 2014

CDC program provides natural self-management techniques for people living with arthritis

In the United States, March is Women's History Month. While it is a time to reflect on the contributions women have made to the fields of politics, art, science, medicine and elsewhere, it is also a time to pay attention to the issues that women today are facing in their daily lives.

29 Mar 2014

New ambitious Government scheme to help people return to work from sick leave

A REPORT from University of Huddersfield experts has ensured that an ambitious Government scheme to help more people return to work from sick leave will include telephone support as a key component.

29 Mar 2014

Antibe Therapeutics increases previously announced non-brokered private placement to up to $5,000,000

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce, based on increased inbound demand, that the previously announced non-brokered private placement (the "Offering") has been increased to up to $5,000,000 on the same terms and conditions as announced in Antibe's press release dated March 21, 2014.

29 Mar 2014

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Today Biogen Idec announced that the U.S. Food and Drug Administration has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body.

29 Mar 2014

TSRI scientists receive $2.3M to study viruses that cause tropical diseases

The outbreak of dengue fever that infected some 20 people in Florida's Martin County late last year unnerved many who feared the tropical disease had once again established a foothold in Florida. The last outbreaks occurred in 2009 and 2010 in Key West—before that, the disease hadn't struck Florida in more than 70 years.

28 Mar 2014

Pain News and Research

Latest Pain News and Research

Early rehabilitation improves neurofunctional outcome after surgery in children with spinal tumors

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Veterans struggle with mental health problems

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Venaxis files 510(k) premarket submission with FDA for APPY1 Test

First Edition: March 31, 2014

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Dongkook Pharmaceutical to launch Probi Mage dietary supplement in South Korea

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

Spouses who express emotions have better sexual, psychological and relational well-being

Choosing better treatment for ankle fractures

FG Xpress launches new revolutionary natural pain relief solution for muscle pains

Integral Molecular announces new patent protecting use of lipoparticles for eliciting antibodies against protein targets

CDC program provides natural self-management techniques for people living with arthritis

New ambitious Government scheme to help people return to work from sick leave

Antibe Therapeutics increases previously announced non-brokered private placement to up to $5,000,000

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

TSRI scientists receive $2.3M to study viruses that cause tropical diseases

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Pain News and Research

Latest Pain News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in